Cannabidiol for Treatment-Resistant Epilepsy: A Randomized Controlled Trial
This double-blind, placebo-controlled trial investigated CBD efficacy in patients with Dravet syndrome and Lennox-Gastaut syndrome who failed standard antiepileptic treatments.
Key Findings:
- 43% reduction in seizure frequency vs. 27% in placebo group
- 5% of patients achieved seizure freedom
- Significant improvement in quality of life scores
- Well-tolerated with manageable side effects